Hemab Therapeutics (NASDAQ:COAG) Rating Increased to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Hemab Therapeutics (NASDAQ:COAG) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

A number of other research analysts also recently issued reports on COAG. Wedbush started coverage on Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $42.00 price objective on the stock. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $36.00 price objective on the stock. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, Evercore started coverage on Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $50.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat, Hemab Therapeutics presently has an average rating of “Strong Buy” and a consensus price target of $41.75.

Hemab Therapeutics Trading Up 7.5%

Shares of COAG opened at $27.84 on Tuesday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Buying and Selling

In other news, major shareholder Ra Capital Management, L.P. bought 3,802 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $24.97 per share, with a total value of $94,935.94. Following the transaction, the insider directly owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. This represents a 0.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders bought 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.